SEARCH

SEARCH BY CITATION

References

  • 1
    Ahren B, Landin-Olsson M, Jansson P-A, Svenson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 20782084.
  • 2
    Mari A, Sallas WM, He YL et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 48884894.
  • 3
    Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006; 38: 423428.
  • 4
    Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005; 7: 692698.
  • 5
    Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 28742880.
  • 6
    Burkey BF, Li X, Bolognese L et al. Combination treatment of a DPP-IV inhibitor NVP-LA237 with pioglitazone completely normalized glucose tolerance in adult obese zucker rats. Diabetes 2002; 51 (Suppl. 2): A338A339.
  • 7
    Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992; 41: 368377.
  • 8
    Hochberg Y, Tamhane AC. Some theory of multiple comparison procedures for fixed-effects linear models In: Y. Hochberg, A. C. Tamhane (Eds.). Multiple comparison procedures. John Wiley & Sons. New York 1987; pp; 1971.
  • 9
    Dejager S, Baron MA, Razac S, Foley JE, Dickinson S, Schweizer A. Efficacy of vildagliptin in drug-naive patients with type 2 diabetes. Diabetologia 2006; 49 (Suppl. 1): 479480.
  • 10
    Garber A, Camisasca RP, Ehrsam E, Collober-Maugeais C, Rochotte E, Lebeaut A. Vildagliptin added to metformin improves glycemic control and may mitigate metformin-induced GI side effects in patients with type 2 diabetes (T2DM). Diabetes 2006; 55 (Suppl. 1): A29.
  • 11
    Takeda Pharmaceuticals. Actos® (Pioglitazone Hydrocholoride Tablets) Prescribing Information. 2002. Lincolnshire, IL, Takeda Pharmaceuticals America, Inc.
  • 12
    Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27: 256263.
  • 13
    Rosenstock J, Baron MA, Schweizer A, Mills D, Dejager S. Vildagliptin is as effective as rosiglitazone in lowering HbA1c but without weight gain in drug-naive patients with type 2 diabetes (T2DM). Diabetes 2006; 55 (Suppl 1): A133 (Abstract 557-P).
  • 14
    Baron MA, Rosenstock J, Bassiri B et al. Efficacy of vildagliptin combined with pioglitazone in patients with type 2 diabetes. Diabetologia 2006; 49 (Suppl. 1): 485486.
  • 15
    Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A 2005; 102: 94069411.
  • 16
    Staels B. Fluid retention mediated by renal PPARγ. Cell Metab 2005; 2: 7778.
  • 17
    Charbonnel B, Schernthaner G, Brunetti P et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005; 48: 10931104.
  • 18
    Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002; 56: 251257.
  • 19
    Miyazaki Y, Glass L, Triplitt C et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 2001; 44: 22102219.
  • 20
    Boden G, Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin Investig Drugs 2006; 15: 243250.
  • 21
    Jovanovic L, Hassman DR, Gooch B et al. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res Clin Pract 2004; 63: 127134.
  • 22
    Roberts VL, Stewart J, Issa M, Lake B, Melis R. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2005; 27: 15351547.
  • 23
    Roberts VL, Stewart J, Issa M, Lake B, Melis R. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2005; 27: 15351547.